Fresenius Kabi recalls morphine syringes that actually contain hydromorphone

Fresenius Kabi is recalling a large lot of prefilled morphine syringes after discovering that the packages contain a different opioid than the label states, according to the FDA's enforcement database [s1]. The agency has classified the action as Class I, its most serious recall category, reserved for defects that could cause serious harm [s1].

The defect is a labelling mix-up rather than a manufacturing impurity. The product is Morphine Sulfate Injection, USP, 2 mg/mL, supplied as 1 mL single-dose Simplist prefilled syringes for intramuscular or intravenous use [s1]. The recall record states that a unit labelled as morphine 2 mg/1 mL was found instead to contain a prefilled syringe of Dilaudid — the brand name for hydromorphone — at 0.5 mg/0.5 mL [s1]. In other words, a clinician reaching for morphine could draw up and give the wrong drug entirely.

The scope

The recall covers 625,500 syringes distributed nationwide, from lot 6402820 with an expiry date of December 2028 [s1]. Fresenius Kabi began the recall on 4 August 2026, and the FDA recorded it on 26 August; its status is listed as ongoing [s1]. Unusually for a recall, the firm reached customers through several channels at once — a combination of email, fax, letter, press release, telephone and site visits — a notification intensity that matches the severity of a wrong-drug error [s1].

Why a wrong-opioid swap is dangerous

Morphine and hydromorphone are both opioid agonists, and both carry FDA boxed warnings — the strongest warning the agency issues — about the serious and life-threatening risks of these medicines [s2][s3]. Hydromorphone's boxed warning explicitly stresses the need to ensure accuracy when the drug is prescribed, dispensed and administered, precisely because errors with potent opioids can be fatal [s2].

The two drugs are not interchangeable. A syringe carrying 0.5 mg of hydromorphone where 2 mg of morphine is expected is not simply a smaller dose of the same medicine — it is a different medicine, with its own dosing and its own effect [s2][s3]. A clinician who calculates a dose from the morphine label, and adjusts it as they would for morphine, is working from the wrong assumptions about the drug in their hand. In a patient who is opioid-naïve, frail, or already sedated, that gap between the labelled drug and the actual drug is exactly the kind of error that leads to over- or under-treatment of pain and, at worst, dangerous respiratory depression.

Prefilled syringes exist in part to reduce medication errors — they remove the step of drawing a drug from a vial and mislabelling it. A mix-up inside a prefilled syringe defeats that safety design, because the person using it has every reason to trust the printed label and no routine way to confirm the contents at the bedside.

What a Class I recall means here

The Class I classification reflects the potential severity of the error, not a tally of harm; the enforcement record does not report any injuries [s1]. Like most drug recalls, this one is voluntary and firm-initiated, meaning Fresenius Kabi identified the problem and pulled the lot rather than being compelled to [s1]. The breadth of the recall — more than 600,000 syringes of a single lot — is a reminder of how far a single packaging error can travel before it is caught.

For hospitals and pharmacies, the standard response to a recall of this kind is to check stock against the affected lot number, quarantine any matching syringes, and follow the recalling firm's return instructions rather than using the product [s1]. Because this is a hospital and clinic presentation, individual patients are unlikely to hold it, but the error underscores why every opioid dose is meant to be checked against its label at the point of care.

What to watch

The open questions are how the syringe mix-up happened on the packaging line, whether it is confined to the single named lot, and what corrective steps the manufacturer puts in place [s1]. Wrong-drug and wrong-strength errors in prefilled products are among the failures medication-safety systems try hardest to design out, and the root-cause findings will matter more than the recall notice itself.

This article reports a regulatory action and is not medical advice. Questions about a specific medicine should go to a pharmacist or clinician.

Sources

• Enforcement Report: Morphine Sulfate Injection, USP, 2 mg/mL Simplist prefilled syringes — Fresenius Kabi USA (recall D-0788-2026, Class I) — U.S. Food and Drug Administration, recorded 26 August 2026
• Hydromorphone Hydrochloride prescribing information: boxed warning — U.S. Food and Drug Administration
• Morphine Sulfate prescribing information: boxed warning — U.S. Food and Drug Administration